Examining the Use of Immunoglobulin for Primary Immunodeficiency Disorders

Specialty Pharmacy Times, June 2020, Volume 3, Issue 2

This continuing education activity is supported by an educational grant from CSL Behring.

THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM CSL BEHRING.

FACULTY

Luigi Brunetti, PharmD, MPH

Associate Professor of Pharmacy, Co-Director, Center of Excellence in Pharmaceutical Translational Research

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey

At the completion of this activity, the participant will be able to:

  • Explain the pathophysiology of common primary immunodeficiency disorders (PIDs)
  • Analyze the use of intravenous (IV) and subcutaneous (SC) immunoglobulins for PID, including dosing, efficacy, and unique characteristics of products
  • Identify pharmacy considerations for IV and SC initiation, administration, and adverse effect management

TARGET AUDIENCE: Specialty pharmacists

ACTIVITY TYPE: Application

RELEASE DATE: March 30, 2020

EXPIRATION DATE: June 14, 2021

ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours

FEE: This lesson is offered for free at www.pharmacytimes.org.